Glaucoma Therapeutics Market Research 2018 - Allergan Inc., Merck KGaA, Novartis AG., Pfizer Inc., Fera Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd., Aristo Pharmaceuticals Pvt. Ltd., Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, an

According to National Federation of the Blind, 2014, an estimated 10 million people in the U.S. are blind or visually impaired. It is estimated that around 1.3 million people are legally blind in the U.S. and the number is projected to increase to 75,000 people annually in the U.S.

Glaucoma therapeutics market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in glaucoma therapeutics market, followed by Asia Pacific. Increasing prevalence of diabetes, increasing ocular disorders, and increasing number of blind and visually impaired people in turn opting for glaucoma treatment are expected to drive growth of the glaucoma therapeutic market in these region.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1675

Glaucoma Therapeutics Market Competitive Landscape

1 Valeant Pharmaceuticals International
2 Allergan Inc
3 Merck KGaA
4 Fera Pharmaceuticals
5 Teva Pharmaceutical Industries Ltd
6 Pfizer
7 Aristo Pharmaceuticals Pvt. Ltd
8 Santen Pharmaceutical Co., Ltd
9 Aerie Pharmaceuticals
10 Novartis AG

Key players in the market are focusing on organic growth strategies in order to gain maximum market share and retain leading position in the market. For instance, in December 2017, Aerie Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for Rhopressa (netarsudil ophthalmic solution) 0.02%, indicated for lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Asia Pacific is expected to gain a significant traction over the forecast period, owing to the government initiatives and awareness programs to eliminate the blindness, which in turn is propelling demand for glaucoma therapies in this region. For instance, in 2014, HelpAge India—a nonprofit organization—launched a special campaign to address the issue of blindness for underprivileged elderly populations of India.

Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1675

However, strict regulations concerning marketing and approvals and the side effects of glaucoma medications are expected to hinder growth of the glaucoma therapeutic market in near future. According to the Glaucoma Research Foundation, 2017 data findings, in the U.S. use of alternative medicines for the treatment of glaucoma has increased 10% to 15% in the past ten years. Furthermore, according to the same source, 50% of the glaucoma patients in the U.S. use some form of alternative therapy in 2017.

Glaucoma Therapeutics Market Taxonomy:

By Disease Type
Primary Open Angle Glaucoma (POAG)
Primary Angle Closure Glaucoma (PACG)

By Drug Class:
Alpha adrenergic Agonist
Beta Blockers
Prostaglandin Analogs
Carbonic Anhydrase Inhibitor
Cholinergic
Combined Medication
Fixed-dose Combinations

By End Users:
Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers
Others

By Geography:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Get Discount @ https://www.coherentmarketinsights.com/insight/request-discount/1675

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.